Bank of America (BofA) Securities updated the earnings model for Pfizer Inc. (NYSE:PFE). The company will announce second-quarter 2025 earnings on August 5.
According to data from Benzinga Pro, analysts estimate adjusted earnings of 57 cents per share on sales of $13.41 billion.
In the second quarter, total revenue decreased by less than 1%, and earnings per share remained unchanged.
Analysts also expect revenue and EPS to stay within 1% of previous forecasts. Revenue will likely decline by a low single-digit percentage in the latter part of the 2020s, they say. This is mainly due to Vyndaqel and Ibrance’s earlier-than-expected loss of exclusivity.
Read Next: Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony
EPS is also expected to shift up or down by a …